code: 4188

AmCad BioMed

AmCad BioMed Corporation

2025 Institutional Investor Conference

Chairman and CEO
Yili Lee
2025/9/2

美吾華·懷特·安克生技集團
Maywufa Biopharma Group

Statement

1.Apart from historical data, the matters listed in this presentation that are forward-looking statements may be subject to significant risks and uncertainties, which could result in differences between these forward-looking statements and actual outcomes.

2.The future projections presented in this document reflect the company's views as of the current date. However, the company is not obligated to update this information in case of any events or changes in the environment.

3.Without the company's permission, the copying, modification, recompilation, reduction, or transmission of any content in this presentation, or the use of any such content for commercial purposes, is strictly prohibited.

4. The content of this presentation includes all entities belonging to the consolidated financial statements.

Agenda

1. Company Overview
2. Key progress
3. International exhibition industry
4. Financials
5. Future development

Company Overview

Company Profile

AmCad BioMed

安克生醫 Pioneering Ultrasound AI

Helping physicians diagnose confidently and efficiently

The first medical device company to obtain FDA approval for ultrasound computer-aided diagnosis (CAD) in the United States. Leveraging world-leading technology combined with artificial intelligence (AI) and medical expertise, we are committed to addressing unmet clinical needs, providing optimal solutions, and serving as a pioneer in intelligent medical imaging.

Founded	Dec. 2008
Business	Product development, Manufacturing and Sales for Innovative Medical Device
Capital	TWD 630M
Subsidiary	Broadsound Corporation
President	Yili Lee
Number of Employees	76

*CAD = Computer-Aided Detection

Products

AmCAD UT　AmCAD UO

Regulatory Certification

FDA　FDA　CE　NMPA　MDR

AmCad BioMed Corporation

5F., No.167, Fuxing N. Rd., Songshan Dist., Taipei City 105403, Taiwan (R.O.C.)
SRN: TW-MF-000013445
has been assessed and certified as meeting the requirements of
MDR EU Quality Management System certificate (Annex IX QMS)
For the following products
Class IIa - MDA0315, MDS1009

The first smart medical software company in Taiwan to receive MDR certification.

Milestones

AmCad BioMed



Milestones

AmCad BioMed

2019

AmCAD-UO obtains CE Mark & FDA 510(k) TFDA

2020

collaboration with Stanford School of Medicine

2021

Advanced AmCAD-UT with AI contouring function obtains FDA 510(k) approval

2023

AmCAD-UO, the research findings are featured in the top-ranked global medical journal in otolaryngology, 'JAMA Oto'.
The AmCAD products (AmCAD UT UO US) have obtained the MDR CE certificate.

2024

South Korea's S1000 "AmCad UO" ultrasound equipment was successfully registered
Taipei City Department of Health approved a self-pay code for UO at National Taiwan University Hospital.
Signed MOU with Meridian Healthcare (MHC) in the United Arab Emirates to launch business cooperation in the Middle East
New Taipei City Department of Health approved a self-pay code for UO at Far Eastern Memorial Hospital, Medical Foundation founded by Mr. Hsu Yuan-Tze.

2025

UO research published in the peer-reviewed journal OTO-HNS.
Advanced AmCAD-UT Live implementation at Jordan Royal Medical Services (RMS).
Chiayi City Department of Health approved a self-pay code for UO at Chiayi Christian Hospital, operated by the Ditmanson Medical Foundation.
Hsinchu County Department of Health approved a self-pay code for UO at China Medical University Hsinchu Hospital.

1. Successfully completed the first Sustainability Report (2024).
2. Completed disclosure in accordance with SASB standards.
3. Completed greenhouse gas inventory.

AmCad six major product lines: Four have obtained U.S. FDA 510(k) clearance

AmCad BioMed

AmCADUO

- Standardized & Automated Upper Airway Ultrasound Scan
- Assessing OSA Severity
- FDA 510(k), CE, TFDA certified

AmCADUS

- FDA 510(k), CE certified
- Capable of differentiating tissues and performing visualized imaging and analysis



AmCADUV

- FDA 510(k), CE certified
- Differentiation between pulsatile signal and noise





AmCADUT

- FDA 510(k), CE, TFDA, NMPA certified
- Thyroid Nodule Ultrasound Risk Assessment



AmCADCA

- Microscopic Cytology Image Analysis
- Visualizing and Quantifying Cytological Clinical Features



AmCADUB

- Real-time AI Breast Ultrasound Imaging
- Breast Nodule Imaging Risk Assessment

Comprehensive Patent Portfolio
30+ Invention Patents

Obtained a new U.S. patent for AmCAD-UO in 2025.

Patent: Ultrasound Scatterer Structure Visualization & Analysis



Patent: Tumor Contour Retrieval

Patent: Multi-Layer Classifier & Echogenicity/ Tumor Feature/ Echo Texture Quantification

Anechoic Area



Texture



Echogenicity



Margin



Echogenic Foci



Nodule Orientation



Patent: Method for Head & Neck Assessment or Intervention



Other Patent Titles	Countries
POSITIONING APPARATUS FOR HEAD AND NECK ASSESSMENT OR INTERVENTION	China EU (Germany) Japan Taiwan USA
METHOD ADAPTED TO DIAGNOSE AIRWAY OBSTRUCTION AND SYSTEM THEREOF	EU (Germany) Japan Taiwan USA
METHODS FOR PREDICTING THE RISK OF OBSTRUCTIVE SLEEP APNEA	USA Taiwan
[USS] ANALYSIS METHODS OF ULTRASOUND ECHO SIGNALS BASED ON STATISTICS OF SCATTERER DISTRIBUTIONS	Taiwan China USA EU (Germany)
[USV] 聲波散射訊號之影像強化方法與成像加速系統 [TW] IMAGE ENHANCEMENT METHOD AND IMAGING ACCELERATION SYSTEM FOR ULTRASOUND SCATTERER SIGNAL [US]Acceleration and enhancement methods and system for ultrasound scatterer structure visualization	USA
[UV] CLUSTERING, NOISE REDUCTION AND VISUALIZATION METHOD FOR ULTRASOUND DOPPLER IMAGES	Taiwan USA
Method and system for quantification and visualization characteristics of cytology images	Taiwan USA

Widely published in prestigious international clinical journals

AmCad BioMed

60+ in top-ranked journals by H-index

JAMA Otolaryngology - Head & Neck Surgery

Association of Backscattered Ultrasonographic Imaging of the Tongue With Severity of Obstructive Sleep Apnea in Adults. vol. 149,7 (2023): 580-586.

Pattern Recognition

Multivariate multi-layer classifier. vol. 131, 108896, July 2022.

Sleep Medicine

Using standardized ultrasound imaging to correlate OSA severity with tongue morphology. vol. 120 15-21. 31 May. 2024.



Ultrasonics

Clinical performance of ultrasonic backscatter parametric and nonparametric statistics in detecting early hepatic steatosis. vol. 142, 107391. Aug. 2024.

European Thyroid Journal

Reliability of a computer-aided system in the evaluation of indeterminate ultrasound images of thyroid nodules. vol. 11,1. e210023. 1 Jan. 2022.

Ultrasound in Medicine & Biology

Diagnostic performance of ultrasound computer-aided diagnosis software compared with that of radiologists with different levels of expertise for thyroid malignancy: A multicenter prospective study. vol. 47,1 (2021): 114-124.



Cancers

Multi-Reader Multi-Case Study for Performance Evaluation of High-Risk Thyroid Ultrasound with Computer-Aided Detection. vol. 12,2 373. 6 Feb. 2020.

Clinical Endocrinology

Differences in the ultrasonographic appearance of thyroid nodules after radiofrequency ablation. vol. 95,3 (2021): 489-497.

May 2025 – Swiss study officially published in OTO-HNS

AmCad BioMed

Original Research—General Otolaryngology

AMERICAN ACADEMY OF OTOLARYNGOLOGY–HEAD AND NECK SURGERY FOUNDATION

Otolaryngology–Head and Neck Surgery 2025, Vol. 00(00) 1–7

DOI: 10.1002/ohn.1251
http://otojournal.org
WILEY

Backscattered Ultrasonographic Imaging of the Tongue and Outcome in Hypoglossal Nerve Stimulation

Samuel Tschopp, MD[1,2*], Vlado Janjic, MD[1*], Yili Lee, MBA[3], Argon Chen, PhD[4], Pei-Yu Chao, PhD[3], Marco Caversaccio, MD[2], Urs Borner, MD[2**], and Kurt Tschopp, MD[1**]

Abstract

Objective. Hypoglossal nerve stimulation (HNS) is an increasingly used therapy. However, not all patients undergoing HNS implantation benefit from the treatment, making an improved patient selection a priority. This study investigates whether backscattered ultrasonographic imaging (BUI) can predict the response to HNS therapy.

Study Design. Cross-sectional study.

Setting. Secondary and tertiary hospital.

Methods. In this multicenter cross-sectional study, we recruited patients who had undergone HNS implantation during their scheduled follow-up consultation. HNS therapy parameters were collected. Standardized submental ultrasonographic examination and home sleep apnea testing were performed. The primary outcome was assessing the response to HNS therapy using ultrasonographic features and preoperative patient characteristics.

Results. In total, 62 participants, 49 male, with a median (interquartile range [IQR]) age of 62 (55-67) and a median (IQR) body mass index of 27.6 (25.2-29.7). The follow-up was a median (IQR) of 19.5 (4.8-41.4) months after implantation. The apnea-hypopnea index (AHI) was preoperatively 40.5 (29.8-58.0) and reduced at follow-up to 21.0 (11.0-35.3). In total, 42% were responders to HNS. Preoperative AHI (34.8/hour vs 49.3/hour, $r = 0.44$) was significantly higher in nonresponders than in responders. The average prediction accuracy of HNS therapy based on baseline AHI alone was 71%. A lower backscatter signal, indicating less fat deposition in the tissue, was observed in the responder group. When the baseline AHI and backscatter signal were combined, the prediction accuracy of response to the HNS reached 78%.

Conclusion. The combination of tissue composition analyzed using the backscattered signal and the preoperative AHI is highly predictive for determining the HNS treatment response.

Trial Registration. ClinicalTrials.gov identifier NCT06154577.

Keywords

hypoglossal nerve stimulation, obstructive sleep apnea, outcome, ultrasonography

Received November 18, 2024; accepted March 23, 2025.

Hypoglossal nerve stimulation (HNS) is increasingly important in managing patients with obstructive sleep apnea (OSA) who do not tolerate continuous positive airway pressure therapy and are not eligible for other alternative treatment options, such as mandibular advancement devices or positional therapy.[1] The number of HNS implantations is increasing, with several thousand new implantations per year, and they have found their place in treatment guidelines.[2] Even with restrictive patient selection according to guidelines and optimal HNS titration, the responder rate remains around 50% to 60%.[1,3-6]

Current anatomical and physiological selection criteria for respiration-triggered HNS include moderate to severe OSA, intolerance to continuous positive airway pressure therapy, body mass index (BMI), drug-induced sleep endoscopy (DISE), and exclusion of central sleep apnea,

[1]Department of Otorhinolaryngology, Head and Neck Surgery, Kantonsspital Baselland Liestal, Liestal, Switzerland
[2]Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University Hospital and University of Bern, Bern, Switzerland
[3]AmCad Biomed Corporation, Taipei, Taiwan
[4]Graduate Institute of Industrial Engineering, National Taiwan University, Taipei, Taiwan

*These authors contributed equally to this article and are equally contributing first authors.
**These authors contributed equally to this article and are equally contributing last authors.

Corresponding Author:
Samuel Tschopp, MD, Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University Hospital and University of Bern, Freiburgstrasse 20, 3010 Bern, Switzerland.
Email: samuel.tschopp@insel.ch

- The paper was officially published in the authoritative journal OTO-HNS, demonstrating professional recognition of our research findings.
- Strengthens product credibility and supports expansion into European and American markets.

Partnering with Leading Global Medical Institutions

AmCad BioMed

Stanford MEDICINE

UNIVERSITY OF THE PACIFIC
Arthur A. Dugoni School of Dentistry

國立臺灣大學醫學院附設醫院 1895 NATIONAL TAIWAN UNIVERSITY HOSPITAL

INSELSPITAL
UNIVERSITÄTSSPITAL BERN
HÔPITAL UNIVERSITAIRE DE BERNE

Kantonsspital Baselland
genau für Sie



Roadmap of Medical Innovation Development



- AmCad has obtained medical device regulatory approval

  AmCAD-UT
  - Submitted to National Health Insurance in March 2024; CDE issued the Health Technology Assessment (HTA) report in April 2025.

  AmCad UO
  - In the past year, newly obtained self-pay medical codes from New Taipei City, Chiayi City, and Hsinchu County.

- Continue to enter major domestic hospitals, health clinics/dentist channels
- Work with well-known teaching hospitals at home and abroad to implement post-market clinical research cases and publish papers to expand product application
- And through international exhibitions, academic exhibitions and online marketing to promote the popularity of accumulated products

Business Model

CDMO / Licensing

Use our expertise in developing product according to our strategic partners' needs/specifications.

Distribution

- Leasing
- Revenue Sharing
- Outright Sales
- Subscription

Exclusive or regional rights, single & multi-product deals.

Collaborative Marketing

Collaborate with enterprise imaging solutions providers to expand market access.

Key progress

AmCAD-UT Product Features

- Accuracy exceeding 90%, enabling consistent automated nodule analysis.
- Built-in risk scoring based on eight international TI-RADS guidelines.
- Patented nodule quantification and visual feature analysis
- Multi-platform compatibility reduces human error with real-time AI guidance.
- AI-assisted real-time automatic annotation.
- Invested in the development of a brand-new UI/UX system.



AmCAD-UT Revamped UX/UI – Integration and Optimization with Clinical Insights





User Interviews & Usability Testing

AmCAD-UT 2025

AmCad BioMed

Domestic sales strategy

NHI Coverage

Annual Health Checkup Subscription

Domestic market strategy

- Health Checkup Center Annual Subscription
- Clinical Focus: Endocrinology / ENT / Radiology
- Expanded departments: family medicine/general surgery
- Cooperation with ultrasound manufacturers
  - Hospital tying strategy
  - Clinic tie-in strategy, cooperation with Handheld ultrasound probe manufacturers
- New business opportunities

  AmCAD-UT Live Scan

A list of AmCad UT® medical institutions

AmCad BioMed



台北市
- 臺大醫院
  - 一般外科
  - 健康管理
- 三軍總醫院
  - 新陳代謝科
  - 健康管理中心
- 臺北市立萬芳醫院
  - 內分泌科(新陳代謝科)
- 臺北市立關渡醫院
- 聯安診所
- 玉山醫事檢驗所

台中市
- 臺中榮民總醫院
  - 內分泌新陳代謝科
  - 健康管理中心
- 中國醫藥大學附設醫院
  - 內分泌新陳代謝科
  - 健康管理中心
- 中山醫學大學附設醫院
  - 醫學影像部
  - 健康管理中心
- 童綜合醫院梧棲院區
  - 內分泌暨新陳代謝科

高雄市
- 高雄榮民總醫院
  - 內分泌新陳代謝科
- 高雄醫學大學附設中和紀念醫院
  - 內分泌新陳代謝科
  - 耳鼻喉頭頸外科
- 義大醫院
  - 健康管理中心

基隆市
- 基隆長庚紀念醫院
  - 內分泌暨新陳代謝科
  - 甲狀腺外科

新北市
- 陳敏玲內科診所

宜蘭市
- 陽明交通大學附設醫院
- 吳震世診所

桃園市
- 林口長庚紀念醫院
  - 內分泌暨新陳代謝科
- 敏盛綜合醫院
  - 內分泌暨新陳代謝科

新竹市
- 新竹馬偕紀念醫院
  - 內分泌暨新陳代謝科

彰化市
- 彰化基督教醫院
  - 內分泌新陳代謝科
  - 健康管理中心

彰化縣
- 彰濱秀傳紀念醫院
  - 健康管理中心
- 鹿港基督教醫院
  - 內分泌新陳代謝科

嘉義市
- 嘉義基督教醫院
  - 新陳代謝科

嘉義縣
- 大林慈濟醫院
  - 新陳代謝科

台南市
- 成大醫院
  - 內分泌及新陳代謝科

AmCAD-UT Application for health insurance benefits

- Assist physicians in diagnosis, aiming to achieve precision medicine and enhance patient well-being through AmCAD-UT intelligent analysis technology.
- In 2025, CDE issued the Health Technology Assessment (HTA) report.
- In the second half of 2025, expert meetings and consensus meetings will be held, and National Health Insurance coverage expected by year-end.



全民健康保險醫療服務給付項目及支付標準
之新增診療項目建議

檢附文件(請勾選)

■建議單位與其他相關單位專家、團體之連繫資訊(表001)

■新增診療項目建議表(表 002)

■診療項目成本分析表(表 003-1)

■作業流程(表 003-2)

□須搭配使用之藥品、特殊材料或診療項目(表 003-3)

□執行診療項目相關醫事人員資格暨設備資料(醫療院所申請必備文件)(表 003-4)

□其他

表格填寫相關疑義請洽：
醫務管理組支付標準科
(02)2706-5866 分機 2654、2632、2637

Reports and software updates from 30+ medical centers/regional hospital UT departments.

AmCad BioMed


台大


萬芳


林口長庚


基隆長庚


彰基


義大

Introduction to Core Products: AmCAD-UO (FDA &CE)

AmCad BioMed





AmCAD-UO Product Features

- Fast, non-overnight, non-invasive screening for obstructive sleep apnea.
- Accuracy up to 95%.
- Visualize and quantify upper airway data to develop the optimal personalized treatment plan for each patient’ s unique airway anatomy.
- Helps identify patients for whom orthodontic and sublingual nerve stimulation treatments are ineffective, as well as the reasons for poor suitability.
- Software UI/UX Optimization Project.

AmCAD-UO 2025

AmCad BioMed

Domestic market strategy



Domestic market strategy

- Health examination centers: medical centers, high-volume regional hospitals and health clinics
- **Clinical expertise:**
  - Sleep Center Product Introduction
  - Pulmonology, **Otolaryngology, Dentistry (Sleep Apnea & Snoring Treatment)**
- **Sales integration**
  - Premium Health Screening Center – Joint Sales of UT/UO
  - Enterprise screening
  - One Stop Solution/Service
- **Cooperation with colleagues related to sleep therapy**
  - CPAP Device Suppliers
  - Snoring Mouthguard Suppliers / Clinics

AmCAD-UO Progress on Health Bureau Self-Pay Code

AmCad BioMed

Region	Approval Number	Name	Approval Date	Self-Pay Price	Market Price
Taichung City Health Bureau	**Taichung City Health Bureau Document No. 1120033618**	**Upper Airway AI Ultrasound**	**2023.4.14**	**4,000**	Taichung City Health Bureau Medical Institutions Approved Self-pay Item Number：2230
Taipei City Department of Health	**Taipei City Health Bureau Document No. 1133110652**	**Automated Ultrasound Localization and Intelligent Analysis of the Upper Airway**	**2024.4.10**	**4,000**	NTU Hospital Self-funded Item Fee Standards (Local Patients) Item：1528 Medical Order Code：000H0601
New Taipei City Department of Health	**New Taipei City Health Bureau Document No. 1131402796**	**Upper Airway AI Ultrasound**	**2024.10.25**	**4,500**	New Taipei City Approved Self-pay Medical Services at Far Eastern Memorial Hospital, a Medical Foundation of the Yu-Chi Hsu Foundation. Item：320
Chiayi City Department of Health	**Chiayi City Health Bureau Document No. 1142701073**	**Automated Ultrasound Localization and Intelligent Analysis of the Upper Airway**	**2025.2.3**	**4,000**	Dadeson Medical Foundation, Chiayi Christian Hospital's Self-pay Medical Service Fee Items.
Hsinchu County Public Health Bureau	**Hsinchu County Health Bureau Document No. 1148550913**	**Upper Airway AI Ultrasound**	**2025.7.10**	**4,000**	China Medical University Hsinchu Hospital Fee Schedule

AmCAD-UO Domestic Business Development (Dentistry, Professional Associations, Corporate Health Checks)

AmCAD-UO Academic Conference

2024 Sleep Medicine Society Annual Meeting

Super Dental Sleep 101 (OSA Well)

AmCAD-UO Healthcare+ Expo Taiwan 2024



Medical Taiwan 2025

AmCad BioMed



International exhibition industry

Record Attendance for Amcad at the MEDICA Exhibition

- Engaged with multiple companies in Europe, South Asia, and Latin America on UO/UT collaboration.
- The TAITRA Chairman personally attended and endorsed the product launch event organized by TAITRA.

RSNA 2024 – Partnership Progress & Future Opportunities

AmCad BioMed

Engaging with major companies for potential collaboration:

GE Healthcare: Exploring the business opportunities of integrating AI with handheld ultrasound solutions.

DeepC and other platform leaders: Beginning strategic collaboration discussions.

Showcasing Our AI Technology's Strength：

Successfully demonstrated compatibility with leading POCUS ultrasound brands.

Validated the clinical value of AI-assisted diagnosis.

Strategic Value:

Establishing AI as a key differentiator in the POCUS market.

Exhibited at the Arab Health Exhibition in Dubai.

- Discussing collaboration with multiple distributors in the Middle East, including AHC, Meridian, and Noum.



AmCAD-UO & UT Successfully Implemented at GluCare AI Diabetes Clinic – Strategic Middle East Demonstration Hub

- In Q4 2024, AmCAD-UO & UT product orders were shipped to GluCare AI Diabetes Clinics, already in use with initial positive clinical feedback.
- **Strategic Value**:Establish the first AI ultrasound application demonstration center in the Middle East.Create a model of collaboration for high-end AI-powered diabetes care clinics.Lay the groundwork for post-2026 Arab Health market development.

AmCAD-UT LIVE+ AI solution, has been successfully installed in Jordan and is now in the trial stage.

- In Q2 2025, we completed the installation and activation of AmCAD-UT LIVE (POCUS, Point-of-care Ultrasound) solution, at a client site. This system integrates real-time AI-powered analysis with a thyroid ultrasound assistance software, laying the groundwork for future clinical applications in rural areas.
- **Strategic Value**：
  Deploying for clinical trials in rural healthcare settings to hasten medical application validation and regional expansion.

AmCAD-UT Clinical Validation Study Approved at a Leading Tertiary Medical Center in Brazil

AmCad BioMed

In collaboration with Brazil's Einstein Hospital, we will conduct a prospective study on 100 cases. The hospital will build its own virtual server to deploy AmCAD-UT.

- **Strategic Value**：
  This project is representative of the South American region and will help us expand into neighboring markets in Central and South America.
- According to the recent "World's Best Hospitals 2024" ranking published by the North American magazine Newsweek, Brazil's Einstein Hospital was ranked 28th globally.

ALBERT EINSTEIN
SOCIEDADE BENEFICENTE ISRAELITA BRASILEIRA

QUADRO RESUMO

PAR2211

DIRETORIA	Medicia Diagnóstica	DEPARTAMENTO	Imagem
REQUISITANTE	Dr Gilberto Szarf	GERENTE DA ÁREA	Dr. Gilberto Szarf
PARCEIRA	SALUS BIOMEDICAL LTDA.		
CNPJ	23.466.209.0001-40		
ENDEREÇO	Av. Piraiba 352, Sala 11, Barueri, São Paulo, SP 06460-121		
OBJETO	Cessão do direito de uso, gratuito e temporário, em favor da SBIBHAE, da solução abaixo descrita, com o fim de que a SBIBHAE possa testar e conhecer suas características e funcionalidades (prova de conceito "POC"), avaliando-a como uma possível ferramenta de apoio para a condução de suas atividades sociais.		
SOLUÇÃO	IA de suporte leitura US tireoide	Segmento	Software
O que faz a solução	Utiliza IA para interpretar imagens de US de tireoide e recomenda PAFF ou seguimento		
Tipo de sistema	ON PREMISE		
Tratamento de Dados Pessoais	SIM	Data do Laudo de TI	
Dados Pessoais tratados	Imagens de Ultrassom pseudoanimizado. Dados necessários e mínimos para login e senha dos usuários.		
Finalidade do tratamento	Recomendar, baseado em normas aceitas, se monitorar ou fazer um PAFF no nódulo analisado		
POC em âmbito de Pesquisa	NÃO	Nome do Pesquisador	14/02/2025
Duração da POC	4 meses	Alçada	DOIS DIRETORES

Initiating AI Platform Integration – NDA Signed with DeepC (Germany)

- In Q3 2025, both parties officially signed a new NDA and initiated API integration. ◦
- **Strategic Value：**
  If successfully implemented, this project will signify that our product meets European platform-level integration standards. This will enable us to connect with more AI platforms in Europe and the U.S., thereby increasing the barrier to entry and accelerating market expansion.



AmCad BioMed

Financials

Consolidated Balance Sheet

AmCad BioMed

Items	2025.06.30	%	2024.12.31	%
Current Assets	434,184	68	418,085	60
Non-current Assets	207,158	32	276,788	40
Total Assets	641,342	100	694,873	100
Current Liabilities	17,707	3	25,143	3
Non-current Liabilities	4,224	1	6,012	1
Total Liabilities	21,931	4	31,155	4
Capital	633,329	99	633,329	91
Capital surplus	141,817	22	141,523	20
Accumulated deficits	(229,053)	(36)	(199,320)	(28)
Other components of equity	(13,989)	(2)	(6,880)	(1)
Parent Equity	532,104	83	568,652	82
Non-controlling interests	87,307	13	95,066	14
Total Equity	619,411	96	663,718	96
Total Liabilities and Equity	641,342	100	694,873	100

- Healthy Cash & Low Debt, Solid Financial Structure.

Consolidated Income Statement

Items	2025H1		2024H1		YoY
	AMT	%	AMT	%	%
Operating revenue	14,939	100	24,448	100	(39)
Gross profit	5,276	35	14,466	59	(64)
Operating Expenses	(47,349)	(317)	(46,930)	(192)	1
Operating Loss	(42,073)	(282)	(32,464)	(133)	-
Non-operating Gain	2,609	18	2,924	12	(11)
Net Loss	(39,449)	(264)	(29,540)	(121)	-
Net Loss – Parent	(31,690)	(212)	(25,879)	(106)	-
Net Loss – Non-controlling interests	(7,759)	(52)	(3,661)	(15)	-
EPS (TWD)	(0.50)		(0.48)		

- Revenue decreased compared to the same period last year; expected to be boosted in H2 through domestic and international business development and successful health insurance reimbursement approvals.

AmCad BioMed

Future development

美吾華·懷特·安克生技集團
Maywufa Biopharma Group

Global Market & Licensing Strategy

AmCad BioMed

Market Opportunity:
The global AI medical imaging market is projected to grow at a CAGR of 29% from 2025–2030, with the ultrasound AI segment growing at approximately 24% annually.

Regional Targets:
Middle East：Building on our successful case study in Dubai, we plan to establish two additional demonstration sites by 2026.
Europe：Following API integration with a German platform provider, our goal is to finalize licensing and collaboration with additional platforms by 2026.
Asia：Focusing on sales through distributors, targeting markets in Southeast Asia and rural areas.。

Licensing Model:：Adopting a Hybrid model that includes one-time licensing and usage-based revenue sharing. This strategy targets large platforms and international medical device manufacturers to mitigate single-market risk.

Technology & Product Strategy

AmCad BioMed

POCUS Integration:
Targeting completion of integration testing with 5 major handheld ultrasound devices by the end of 2025 (compatibility with several handheld devices already verified).
Launch interface improvements to enhance user experience.

On-device AI:
Continue developing edge computing to achieve <1-second image analysis, increasing penetration in rural and mobile healthcare settings.

Product Line Development:
AmCAD-UT: After completing the health insurance sandbox program, rapid adoption by medical institutions is expected in 2026.
AmCAD-UO: Introduce to dental and sleep therapy channels to boost sales growth and channel reach.
AmCAD-UB: Develop high-sensitivity entry-level screening AI module, targeting primary care market entry.

AMCAD AI software is compatible with any brand of handheld ultrasound.



Future Strategy

Domestic Market

Health Insurance & Hospital Adoption:

UT: Target health insurance approval by the end of 2025; deploy to medical centers and regional hospitals across Taiwan in 2026.

UO: Continue expanding into dental and sleep centers; aim to penetrate all six major cities in Taiwan by 2026.

Health Screening Center Collaboration: Launch "two-in-one" (UT + UO) service packages targeting premium health screening centers to increase per-customer revenue.

Brand & International Visibility:

- Actively participate in major international medical exhibitions (RSNA, MEDICA, Arab Health), attending at least three top-tier events annually.
- Collaborate with international KOLs and leading medical centers to publish clinical papers in renowned international journals.

AmCad BioMed

Thank you

美吾華·懷特·安克生技集團
Maywufa Biopharma Group